Skip to search formSkip to main contentSkip to account menu

ALO-02

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Proper management of severe pain represents one of the most challenging clinical dilemmas. Two equally important goals must be… 
Review
2017
Review
2017
BackgroundThe efficacy of ALO-02, an abuse-deterrent formulation containing extended-release oxycodone and sequestered naltrexone… 
2016
2016
Abstract Objective. To evaluate the abuse potential of ALO-02, an abuse-deterrent formulation comprising pellets of extended… 
2016
2016
ABSTRACT Background: ALO-02, comprising pellets of extended-release oxycodone surrounding sequestered naltrexone, is intended to… 
2015
2015
Abstract The objective of this multicenter, double-blind, placebo-controlled, randomized withdrawal study was to evaluate the… 
2015
2015
ALO‐02 is an abuse‐deterrent formulation consisting of capsules filled with pellets of extended‐release oxycodone surrounding… 
2015
2015
Background and ObjectivesALO-02 capsules, intended to deter abuse, contain pellets of extended-release oxycodone hydrochloride… 
Review
2014
Review
2014
Abstract Background: For properly selected patients experiencing chronic pain, extended-release opioid formulations may represent… 
2014
2014
OBJECTIVE To evaluate the long-term safety of oxycodone-hydrochloride and sequestered naltrexone-hydrochloride (ALO-02… 
Review
2014
Review
2014
Background: ALO-02, an opioid formulation intended to deter abuse, comprising capsules filled with pellets of extended-release…